Next, ALYREF was found to be upregulated in hepatocellular carcinoma and oral squamous cell carcinoma, and it may have an effect on tumorigenesis via cell cycle regulation and mitosis (Saito et al., 2013; He et al., 2020). Here, ALYREF is linked to oral cavity squamous cell carcinoma.